Management of hypercholesterolemia, appropriateness of therapeutic approaches and new drugs in patients with high cardiovascular risk
Submitted: 27 June 2018
Accepted: 2 July 2018
Published: 10 September 2018
Accepted: 2 July 2018
Abstract Views: 1271
PDF: 632
HTML: 45
HTML: 45
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Similar Articles
- Nathan Artom, Giuliano Pinna, The erectile dysfunction as a cardiovascular risk factor , Italian Journal of Medicine: Vol. 8 No. 4 (2014)
- Mauro Campanini, Giuliano Pinna, Roberto Nardi, on behalf of the FADOI Cardiovascular Prevention Position Statements Group, The FADOI (Federation of Associations of Hospital Doctors on Internal Medicine) position paper on cardiovascular prevention in the higher risk complex patients , Italian Journal of Medicine: Vol. 9 No. 4 (2015)
You may also start an advanced similarity search for this article.